OCT West Coast: how can decentralisation help optimise rare disease trials?
Throughout the Covid-19 pandemic, decentralised clinical trials (DCTs) have been imperative for the continuation of...
Throughout the Covid-19 pandemic, decentralised clinical trials (DCTs) have been imperative for the continuation of...
On 1 February, the Clinical Kidney Journal published results from a real-world setting study, the...
The ongoing Covid-19 pandemic has yielded an unexpected advancement in the pharmaceutical industry with the...
The monumental challenges brought about by the Covid-19 pandemic have forced the healthcare and life...
On 14 December, the US Food and Drug Administration (FDA) approved a shorter two-hour infusion...
In early December, KBP Biosciences shared results for their BLOCK-CKD Phase IIb study, which has...